TRANSFORMING SCIENCE INTO HEALTH: Azur as pioneers in SPMs

In this context, Solutex – as the parent company of Azur – has been a strategic partner in the industrial translation of this knowledge, developing Lipinova®, a unique ingredient standardized in active and quantifiable SPMs, representing an effective transition from basic research to clinical and nutritional applications.

As a result of nearly 20 years of research, Solutex has established itself as a pioneer in the science and technology of SPMs at a commercial level, being the first to develop - in close collaboration with Dr. Serhan, co-author of our patents and director of our Scientific Advisory Board - the only ingredient (Lipinova®) worldwide standardized in these SPMs lipid mediators and demonstrating its effectiveness in inflammatory processes in clinical and scientific studies.

Today, Solutex leads the way in this field with more than 130 international patents, reflecting its innovative capacity and commitment to translational research.

At Azur, dedicated to people's present and future health and well-being, we are committed to providing people with the most advanced science in inflammation management.